Suppr超能文献

早产儿晚期应用苯肾上腺素和托吡卡胺滴眼液致急性药物反应:1 例报告。

Acute drug reaction to phenylephrine and tropicamide collyrium in a late-preterm newborn: a case report.

机构信息

Department of Medicine, Surgery and Health Sciences, University of Trieste, Trieste, Italy.

Institute for Maternal and Child Health, IRCCS Burlo Garofolo, Trieste, Italy.

出版信息

BMC Pediatr. 2022 Jul 7;22(1):398. doi: 10.1186/s12887-022-03459-z.

Abstract

BACKGROUND

Collyrium administration is a common procedure in the neonatal ward, both in preterm and at term babies. Various molecules are used to induce mydriasis and cycloplegia: among them, phenylephrine and tropicamide are the most popular, and their administration is generally considered safe.

CASE PRESENTATION

A 35 + 2 weeks-old, 2510 g, well-appearing male newborn required an ophthalmologic evaluation after a doubtful red reflex test. A collyrium with 1% phenylephrine and 0.95% tropicamide was administered prior to the consult, one drop per eye. Two minutes after the administration, the baby developed a severe apnea that required tactile stimulation. Moreover, the area around his eyes became visibly pale. Three minutes later, the baby became severely bradycardic (59 bpm), but remained in good general condition, so that resuscitation maneuvers were not required. Bradycardia lasted for almost three hours and then gradually resolved.

CONCLUSIONS

Cardiopulmonary manifestations, such as bradycardia and even cardiopulmonary arrest, are severe complications that can happen after phenylephrine collyrium administration in preterm newborns. However, they have been described in babies below 1500 g or with concurrent respiratory manifestations. Our patient, on the other hand, was late preterm, and never required a ventilatory support prior to the collyrium administration. Practitioners who deal with premature babies, even if late preterm, must be aware of these possible complications and administer phenylephrine collyrium carefully, where cardiopulmonary resuscitation equipment and personnel are available.

摘要

背景

在早产儿和足月儿的新生儿病房中,滴眼剂给药是一种常见的操作。有多种分子可用于散瞳和睫状肌麻痹:其中,苯肾上腺素和托吡卡胺最为常用,其给药通常被认为是安全的。

病例介绍

一名 35+2 周、体重 2510 克、外观良好的男性新生儿,因可疑的红色反射试验,需要进行眼科评估。在就诊前,给婴儿双眼各滴一滴 1%苯肾上腺素和 0.95%托吡卡胺的滴眼剂。给药后 2 分钟,婴儿出现严重的呼吸暂停,需要触觉刺激。此外,他的眼睛周围区域明显苍白。3 分钟后,婴儿出现严重心动过缓(59 次/分),但一般情况良好,因此无需进行复苏操作。心动过缓持续了将近 3 小时,然后逐渐缓解。

结论

苯肾上腺素滴眼剂给药后,早产儿可能会出现心肺表现,如心动过缓甚至心跳骤停等严重并发症。但这些并发症已在体重<1500 克或伴有呼吸表现的婴儿中描述过。而我们的患者是晚期早产儿,在滴眼剂给药前从未需要过通气支持。处理早产儿的医务人员,即使是晚期早产儿,也必须意识到这些可能的并发症,并在有心肺复苏设备和人员的情况下谨慎使用苯肾上腺素滴眼剂。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/6dc8/9264638/3c9fb611b59a/12887_2022_3459_Fig1_HTML.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验